Beranda › Kanker Kolorektal › Kansas
Uji klinis Kanker Kolorektal di Kansas
19 studi untuk Kanker Kolorektal mencari peserta di lokasi di Kansas.
Kota di Kansas
Teks studi resmi (Bahasa Inggris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Veteran Administration Eastern Kansas Healthcare, Leavenworth
- dan 4 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069Family Communications After Genetic Testing
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Mercy Hospital Pittsburg, Pittsburg
- dan 1 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07143487Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05803382Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Westwood
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06218914A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Cancer Center of Kansas, Wichita
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06750094A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Cancer Center of Kansas, Wichita
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06662786Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- University of Kansas, Fairway
Menerima pesertaFase 1
Usia 12 hingga 120 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT04222413Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- The University of Kansas Clinical Research Center, Westwood
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06445062Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06696768Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Westwood
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07228832A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Kansas Cancer Center, Kansas City
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
- dan 2 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT05691491Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
- Cancer Centers of Kansas, Wichita
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT06937177Lead-212 PSV359 Therapy for Patients With Solid Tumors
- University of Kansas, Kansas City
Menerima pesertaFase 1/2
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06710756Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
- The University of Kansas Clinical Research Center, Fairway
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jun 2026 · NCT06607458Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Mercy Hospital Pittsburg, Pittsburg
Menerima pesertaFase 3Sukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Mar 2026 · NCT07018869A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- The University of Kansas Cancer Center, Fairway
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mar 2026 · NCT06244771Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- HaysMed, Hays
- Lawrence Memorial Hospital, Lawrence
- The University of Kansas Cancer Center - Olathe, Olathe
- dan 6 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204A Study of IBI363 in Subjects with Advanced Solid Malignancies
- University of Kansas Medical Center (KUMC), Fairway
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Des 2024 · NCT06281678Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.